NClip

Colon Cancer

4 min read

Colon Cancer

Key Points

  • Colorectal cancer (colon or rectal origin) accounts for about 8% of new U.S. cancer cases and has an overall 5-year survival near 65%.
  • Screening emphasis supports earlier detection before symptoms; symptomatic presentation often reflects more advanced disease.
  • Risk increases with colorectal polyps, Lynch syndrome, chronic inflammatory-bowel-disease, heavy alcohol use, obesity, smoking, and family history.
  • Definitive diagnosis requires rectal exam and colonoscopy with biopsy; CT/MRI staging guides treatment planning.
  • Most cases require surgery, with chemotherapy for advanced disease and radiation used palliatively in selected metastatic contexts.

Pathophysiology

Colon cancer develops through accumulated genetic mutations that transform normal colonic or rectal epithelium into malignant tissue. Abnormal cells evade immune elimination, then proliferate within colorectal tissue and progressively invade deeper layers.

Disease extent is commonly described with the TNM framework (primary tumor, nodal spread, distant metastasis). Common metastatic targets include liver, lungs, and lymphatic structures.

Classification

  • Screen-detected disease: Found incidentally during routine stool screening or colonoscopy.
  • Symptom-detected disease: Presentation with bowel-habit change, bloody stools, abdominal pain/cramping, bloating/gas pain, fatigue, or weight loss.
  • Localized vs metastatic disease: Determines whether management is surgery-first, systemic therapy, or multimodal treatment.

Nursing Assessment

NCLEX Focus

A positive stool-based screening test requires timely colonoscopic follow-up; delay can miss a treatable cancer window.

  • Assess risk profile: family history, prior polyps, IBD history, lifestyle factors, and prior radiation.
  • Assess symptom cues: bowel-pattern change, bloody stool, abdominal tenderness/cramping, bloating/gas pain, unexplained weight loss, and fatigue.
  • Assess for physical findings in progressive disease, including palpable abdominal mass, ascites, hepatomegaly, and dehydration cues (tachycardia, hypotension, poor skin turgor).
  • Assess age-band screening-benefit context (moderate net benefit ages 45 to 49, substantial benefit ages 50 to 75, and individualized small benefit ages 76 to 85) and whether prior testing history supports continued screening.
  • Track diagnostic pathway:
    • Stool-based screening (including DNA/occult blood panels) as entry points
    • Rectal exam plus colonoscopy with biopsy for definitive diagnosis
    • CBC, metabolic panel, and liver-function studies for organ-function and treatment baseline assessment
    • CT/MRI imaging for staging and disease mapping
    • CEA trend for treatment-response and recurrence monitoring, not stand-alone diagnosis
  • Monitor for metastatic symptom patterns (hepatic, pulmonary, nodal involvement).

Nursing Interventions

  • Coordinate expedited diagnostic follow-up after abnormal screening.
  • Teach interval options for average-risk pathways: annual high-sensitivity FOBT/FIT, multitarget stool DNA about every 3 years, colonoscopy every 10 years, and CT colonography every 5 years when selected.
  • Reinforce bowel-prep and sedation safety education for colonoscopy workflows.
  • Provide perioperative teaching for surgical candidates, including potential ostomy outcomes.
  • Support chemotherapy/immunotherapy symptom monitoring and adherence planning.
  • Prioritize infection surveillance during active treatment, especially with chemotherapy (temperature, vital signs, pain trend, incision status, and IV access-site checks).
  • Teach home infection-prevention behaviors and early reporting triggers for fever or new infectious symptoms.
  • Teach red-flag escalation: ongoing bleeding, obstructive symptoms, severe pain, fever, or rapid functional decline.
  • Provide psychosocial support, including body-image support for patients with a new stoma.
  • Evaluate bowel-motility outcomes during treatment (distention, cramping, pain, bowel sounds, stool pattern) and adjust care plans when dysfunction persists.

Screening Follow-Through

Stool or blood-based screening alone does not confirm or exclude cancer without appropriate diagnostic completion.

Pharmacology

CategoryExamplesNursing considerations
Systemic anticancer therapyChemotherapy and immunotherapy/biologic protocolsMonitor for cytopenias, infection risk, GI toxicity, and treatment adherence
Radiation therapy (selected metastatic contexts)Palliative radiation regimensTrack symptom relief goals and monitor local tissue adverse effects
Symptom and supportive medicationsAntiemetics, pain regimens, bowel-support agentsTailor to treatment phase and bowel-function changes

Clinical Judgment Application

Clinical Scenario

A 57-year-old with a positive stool DNA screening result reports intermittent blood in stool and fatigue.

  • Recognize Cues: High-risk screen plus compatible symptom pattern.
  • Analyze Cues: Malignancy must be ruled in/out with definitive tissue diagnosis.
  • Prioritize Hypotheses: Priority is rapid diagnostic completion and staging.
  • Generate Solutions: Arrange colonoscopy/biopsy pathway, baseline labs, and education for next steps.
  • Take Action: Coordinate diagnostic testing, begin infection-risk monitoring during treatment planning, and reinforce follow-up reliability.
  • Evaluate Outcomes: Diagnosis/stage are established without delay, complications are prevented, and treatment starts on time.

Self-Check

  1. Why is CEA not sufficient as a stand-alone diagnostic test for colon cancer?
  2. Which risk factors should trigger heightened vigilance for colorectal malignancy?
  3. What nursing actions reduce delay after a positive stool-based screen?

Graph View